In Law360, White & Case Antitrust partner, Kevin Adam, discusses how biotech companies that have products affected by Medicare price negotiations under the Inflation Reduction Act (IRA) are messaging the short and long-term potential outcomes to investors.
"I don't believe the impact of this first round of price controls is likely to be predictive of the overall severity of the impact of the Inflation Reduction Act and specifically the Medicare negotiation provisions," said Adam.
Additionally, he stated the impact of the IRA price negotiations has already been modeled into companies' financials, so it makes sense that executives are affirming their annual guidance if the final negotiated prices they've received from the federal government are generally in line with what they expected.
See the full Law360 article here.
Press contact
For more information please speak to your local media contact.
